Drug Development Research · 1989 · 48 citations · 9 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryNeuropharmacologyPotency OptimizationReceptor PharmacologySerotonergic PharmacologySerotonergic Signaling5-Hydroxytryptamine 1A Receptor Agonists5-Hydroxytryptamine Receptor PharmacologyPharmacology Of Serotonergic AgentsSerotonergic AgonistsSerotonin AgonistsSerotonin Receptor PharmacologySerotonin Receptor SubtypesSerotonin Receptors
Abstract Arylpiperazines have been demonstrated to bind both at 5‐HT 1A and 5‐HT 1B serotonin receptors. In an attempt to design novel 5‐HT 1A agonists and antagonists, based on an arylpiperazine nucleus, we investigated the stimulus properties of a series of such agents (in rats trained to discriminate 0.5 mg/kg of the 5‐HT 1B agent TFMPP from saline) to determine what structural features were important for 5‐HT 1B activity. This done, we modified these agents to eliminate those features and, at the same time, incorporated structural features that appeared important for 5‐HT 1A affinity. The resulting agents displayed high affinity for 5‐HT 1A sites. One agent in particular, NAN‐190, neither mimicked nor antagonized the TFMPP stimulus, but was capable of antagonizing the stimulus produced by the 5‐HT 1A agonist 8‐OH DPAT (0.2 mg/kg). These preliminary results suggest that NAN‐190 may be a potential 5‐HT 1A antagonist.
9
Frank D. Yocca, Deborah K. Hyslop, David W. Smith et al. · European Journal of Pharmacology · 1987 · 128 citations
Medicine, Neuroscience, Pharmacology +10
Selectivity of serotonergic drugs for multiple brain serotonin receptors
Milt Titeler, Robert A. Lyon, Katharine H. Davis et al. · Biochemical Pharmacology · 1987 · 118 citations
Medicine, Neuroscience, Pharmacology +13